Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Pleyer, L; Burgstaller, S; Girschikofsky, M; Linkesch, W; Stauder, R; Pfeilstocker, M; Schreder, M; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Krippl, P; Geissler, D; Voskova, D; Schlick, K; Thaler, J; Machherndl-Spandl, S; Theiler, G; Eckmüllner, O; Greil, R.
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Ann Hematol. 2014; 93(11):1825-1838 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Linkesch Werner
Theiler Georg
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 3
| | |
Abstract:
Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian Azacitidine Registry (clinicaltrials.gov identifier NCT01595295). We herein update this report with a population almost twice as large (n = 302). This cohort included 172 patients with >30 % BM blasts; 93 % would have been excluded from the pivotal AZA-001 trial (which led to European Medicines Agency (EMA) approval of azacitidine for high-risk myelodysplastic syndromes (MDS) and AML with 20-30 % BM blasts). Despite this much more unfavorable profile, results are encouraging: overall response rate was 48 % in the total cohort and 72 % in patients evaluable according to MDS-IWG-2006 response criteria, respectively. Median OS was 9.6 (95 % CI 8.53-10.7) months. A clinically relevant OS benefit was observed with any form of disease stabilization (marrow stable disease (8.1 months), hematologic improvement (HI) (9.7 months), or the combination thereof (18.9 months)), as compared to patients without response and/or without disease stabilization (3.2 months). Age, white blood cell count, and BM blast count at start of therapy did not influence OS. The baseline factors LDH >225 U/l, ECOG ≥2, comorbidities ≥3, monosomal karyotype, and prior disease-modifying drugs, as well as the response-related factors hematologic improvement and further deepening of response after first response, were significant independent predictors of OS in multivariate analysis. Azacitidine seems effective in WHO-AML, including patients with >30 % BM blasts (currently off-label use). Although currently not regarded as standard form of response assessment in AML, disease stabilization and/or HI should be considered sufficient response to continue treatment with azacitidine.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Antimetabolites, Antineoplastic - therapeutic use
Antimetabolites, Antineoplastic - epidemiology
Azacitidine - therapeutic use
Cohort Studies -
Female -
Humans -
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - epidemiology
Male -
Middle Aged -
Registries -
Retrospective Studies -
Survival Rate - trends
Treatment Outcome -
World Health Organization -

Find related publications in this database (Keywords)
Austrian Azacitidine Registry
Azacitidine
AML
Overall survival
Prognostic factors
Bone marrow blasts
© Meduni Graz Impressum